Abstract
Introduction and Objective: Kawasaki disease (KD) is associated with diffuse and systemic vasculitis of unknown aetiology and primarily affects infants and children. Intravenous immunoglobulin (IVIG) treatment reduces the risk of developing coronary aneurysms, but some children have IVIG-resistant KD, which increases their risk of developing coronary artery injury. Here, we investigated the effect of recombinant human soluble thrombomodulin (rTM), which has anticoagulant, anti-inflammatory, and cytoprotective properties on the development of coronary arteritis in a mouse model of vasculitis. Methods: An animal model of KD-like vasculitis was created by injecting mice with Candida albicans water-soluble fraction (CAWS). This model was used to investigate the mRNA expression of interleukin (IL)-10, tumour necrosis factor alpha (TNF-α), and tissue factor (TF), in addition to histopathology of heart tissues. Results: rTM treatment significantly reduces cardiac vascular endothelium hypertrophy by 34 days after CAWS treatment. In addition, mRNA expression analysis revealed that rTM administration increased cardiac IL-10 expression until day 27, whereas expression of TNF-α was unaffected. Moreover, in the spleen, rTM treatment restores IL-10 and TF expression to normal levels. Conclusion: These findings suggest that rTM suppresses CAWS-induced vasculitis by upregulating IL-10. Therefore, rTM may be an effective treatment for KD.
References
1.
Kawasaki
T
, Kosaki
F
, Okawa
S
, Shigematsu
I
, Yanagawa
H
. A new infantile acute febrilemucocutaneous lymph node syndrome (MLNS) prevailing in Japan
. Pediatrics
. 1974 Sep
;54
(3
):271
–6
.2.
Newburger
JW
, Takahashi
M
, Burns
JC
. Kawasaki disease
. J Am Coll Cardiol
. 2016 Apr
;67
(14
):1738
–49
. .3.
Denby
KJ
, Clark
DE
, Markham
LW
. Management of Kawasaki disease in adults
. Heart
. 2017 Nov
;103
(22
):1760
–9
. .4.
Burns
JC
, Franco
A
. The immunomodulatory effects of intravenous immunoglobulin therapy in Kawasaki disease
. Expert Rev Clin Immunol
. 2015
;11
(7
):819
–25
. .5.
Son
MB
, Gauvreau
K
, Burns
JC
, Corinaldesi
E
, Tremoulet
AH
, Watson
VE
, Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study
. J Pediatrics
. 2011Apr
;158
(4
):644
–9
.6.
Nakamura
J
, Watanabe
S
, Kimura
H
, Kobayashi
M
, Karasawa
T
, Kamata
R
, Adeno-associated virus vector-mediated interleukin-10 induction prevents vascular inflammation in a murine model of Kawasaki disease
. Sci Rep
. 2018 May
;8
(1
):7601
.7.
Frazer
J
. Infectious disease: blowing in the wind
. Nature
. 2012 Apr
;484
(7392
):21
–3
. .8.
Rodó
X
, Curcoll
R
, Robinson
M
, Ballester
J
, Burns
JC
, Cayan
DR
, Tropospheric winds from northeastern China carry the etiologic agent of Kawasaki disease from its source to Japan
. Proc Natl Acad Sci U S A
. 2014 Jun
;111
(22
):7952
–7
.9.
Motomura
Y
, Kanno
S
, Asano
K
, Tanaka
M
, Hasegawa
Y
, Katagiri
H
, Identification of pathogenic cardiac CD11c+ macrophages in Nod1-mediated acute coronary arteritis mediated acute coronary arteritis
. Arterioscler Thromb Vasc Biol
. 2015 Jun
;35
(6
):1423
–33
.10.
Lee
Y
, Schulte
DJ
, Shimada
K
, Chen
S
, Crother
TR
, Chiba
N
, Interleukin-1beta is crucial for the induction of coronary artery inflammation in a mouse model of Kawasaki disease
. Circulation
. 2012 Mar
;125
(12
):1542
–50
.11.
Nagi-Miura
N
, Shingo
Y
, Adachi
Y
, Ishida-Okawara
A
, Oharaseki
T
, Takahashi
K
, Induction of coronary arteritis with administration of CAWS (Candida albicans water-soluble fraction) depending on mouse strains
. Immunopharmacol Immunotoxicol
. 2004
;26
(4
):527
–43
.12.
Esmon
NL
, Owen
WG
, Esmon
CT
. Isolation of a membrane-bound cofactor for thrombin-catalyzed activation of protein C
. J Biol Chem
. 1982 Jan
;257
(2
):859
–64
. .13.
Esmon
CT
, Owen
WG
. The discovery of thrombomodulin
. J Thromb Haemost
. 2004 Feb
;2
(2
):209
–13
. .14.
Suzuki
K
, Nishioka
J
, Matsuda
M
, Murayama
H
, Hashimoto
S
. Protein S is essential for the activated protein C-catalyzed inactivation of platelet-associated factor Va
. J Biochem
. 1984 Aug
;96
(2
):455
–60
. .15.
Suzuki
K
, Kusumoto
H
, Deyashiki
Y
, Nishioka
J
, Maruyama
I
, Zushi
M
, Structure and expression of human thrombomodulin, a thrombin receptor on endothelium acting as a cofactor for protein C activation
. EMBO J
. 1987 Jul
;6
(7
):1891
–7
.16.
Suzuki
K
, Hayashi
T
, Nishioka
J
, Kosaka
Y
, Zushi
M
, Honda
G
, A domain composed of epidermal growth factor-like structures of human thrombomodulin is essential for thrombin binding and for protein C activation
. J Biol Chem
. 1989 Mar
;264
(9
):4872
–6
.17.
Saito
H
, Maruyama
I
, Shimazaki
S
, Yamamoto
Y
, Aikawa
N
, Ohno
R
, Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial
. J Thromb Haemost
. 2007 Jan
;5
(1
):31
–41
.18.
Conway
EM
, Van de Wouwer
M
, Pollefeyt
S
, Jurk
K
, Van Aken
H
, De Vriese
A
, The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kappaB and mitogen-activated protein kinase pathways
. J Exp Med
. 2002 Sep
;196
(5
):565
–77
.19.
Abeyama
K
, Stern
DM
, Ito
Y
, Kawahara
K
, Yoshimoto
Y
, Tanaka
M
, The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism
. J Clin Invest
. 2005 May
;115
(5
):1267
–74
.20.
Miura
NN
, Komai
M
, Adachi
Y
, Osada
N
, Kameoka
Y
, Suzuki
K
, IL-10 is a negative regulatory factor of CAWS-vasculitis in CBA/J mice as assessed by comparison with Bruton’s tyrosine kinase-deficient CBA/N mice
. J Immunol
. 2009 Sep
;183
(5
):3417
–24
.21.
Kudo
D
, Toyama
M
, Aoyagi
T
, Akahori
Y
, Yamamoto
H
, Ishii
K
, Involvement of high mobility group box 1 and the therapeutic effect of recombinant thrombomodulin in a mouse model of severe acute respiratory distress syndrome
. Clin Exp Immunol
. 2013 Aug
;173
(2
):276
–87
.22.
Ikezoe
T
, Yang
J
, Nishioka
C
, Yokoyama
A
. Thrombomodulin alleviates murine GVHD in association with an increase in the proportion of regulatory T cells in the spleen
. Bone Marrow Transplant
. 2015 Jan
;50
(1
):113
–20
. .23.
Fujiwara
K
, Kobayashi
T
, Fujimoto
H
, Nakahara
H
, D’Alessandro-Gabazza
CN
, Hinneh
JA
, Inhibition of cell apoptosis and amelioration of pulmonary fibrosis by thrombomodulin
. Am J Pathol
. 2017 Oct
;187
(10
):2312
–22
.24.
Kida
T
, Seno
T
, Nagahara
H
, Inoue
T
, Nakabayashi
A
, Kukida
Y
, Roles of high-mobility group box 1 and thrombin in murine pulmonary fibrosis and the therapeutic potential of thrombomodulin
. Am J Physiol Lung Cell Mol Physiol
. 2018 Mar 1
;314
(3
):L473
–83
.25.
Ohashi
R
, Fukazawa
R
, Watanabe
M
, Tajima
H
, Nagi-Miura
N
, Ohno
N
, Etanercept suppresses arteritis in a murine model of kawasaki disease: a comparative study involving different biological agents
. Int J Vasc Med
. 2013
;2013
:543141
.26.
Greineder
CF
, Johnston
IH
, Villa
CH
, Gollomp
K
, Esmon
CT
, Cines
DB
, ICAM-1-targeted thrombomodulin mitigates tissue factor-driven inflammatory thrombosis in a human endothelialized microfluidic model
. Blood Adv
. 2017 Aug
;1
(18
):1452
–65
.27.
Galeotti
C
, Kaveri
SV
, Cimaz
R
, Koné-Paut
I
, Bayry
J
. Predisposing factors, pathogenesis and therapeutic intervention of Kawasaki disease
. Drug Discov Today
. 2016 Nov
;21
(11
):1850
–7
. .28.
Toda
M
, Shao
Z
, Yamaguchi
KD
, Takagi
T
, D’Alessandro-Gabazza
CN
, Taguchi
O
, Differential gene expression in thrombomodulin (TM; CD141)(+) and TM(−) dendritic cell subsets
. PLoS One
. 2013 Aug
;8
(8
):e72392
.29.
Stock
AT
, Jama
HA
, Hansen
JA
, Wicks
IP
. TNF and IL-1 play essential but temporally distinct roles in driving cardiac inflammation in a murine model of kawasaki disease
. J Immunol
. 2019 Jun
;202
(11
):3151
–60
. .30.
Gorelik
M
, Lee
Y
, Abe
M
, Andrews
T
, Davis
L
, Patterson
J
, IL-1 receptor antagonist, anakinra, prevents myocardial dysfunction in a mouse model of Kawasaki disease vasculitis and myocarditis
. Clin Exp Immunol
. 2019 Oct
;198
(1
):101
–10
.31.
Shafferman
A
, Birmingham
JD
, Cron
RQ
. High dose Anakinra for treatment of severe neonatal Kawasaki disease: a case report
. Pediatr Rheumatol Online J
. 2014 Jul
;12
:26
. .32.
Guillaume
MP
, Reumaux
H
, Dubos
F
. Usefulness and safety of anakinra in refractory Kawasaki disease complicated by coronary artery aneurysm
. Cardiol Young
. 2018 May
;28
(5
):739
–42
. .33.
Sánchez-Manubens
J
, Gelman
A
, Franch
N
, Teodoro
S
, Palacios
JR
, Rudi
N
, A child with resistant Kawasaki disease successfully treated with anakinra: a case report
. BMC Pediatr
. 2017 Apr 8
;17
(1
):102
.34.
Blonz
G
, Lacroix
S
, Benbrik
N
, Warin-Fresse
K
, Masseau
A
, Trewick
D
, Severe late-onset Kawasaki disease successfully treated with anakinra
. J Clin Rheumatol
. 2020 Mar
;26
(2
):e42
–3
.35.
Noval Rivas
M
, Arditi
M
. Kawasaki disease: pathophysiology and insights from mouse models
. Nat Rev Rheumatol
. 2020 Jul
;16
(7
):391
–405
. .36.
Blann
AD
, Amiral
J
, McCollum
CN
. Prognostic value of increased soluble thrombomodulin and increased soluble E-selectin in ischaemic heart disease
. Eur J Haematol
. 1997Aug
;59
(2
):115
–20
. .37.
Blann
AD
, Seigneur
M
, Steiner
M
, Boisseau
MR
, McCollum
CN
. Circulating endothelial cell markers in peripheral vascular disease: relationship to the location and extent of atherosclerotic disease
. Eur J Clin Invest
. 1997 Nov
;27
(11
):916
–21
. .38.
Nakahara
M
, Ito
T
, Kawahara
K
, Yamamoto
M
, Nagasato
T
, Shrestha
B
, Recombinant thrombomodulin protects mice against histone-induced lethal thromboembolism
. PLoS One
. 2013 Sep
;8
(9
):e75961
.© 2021 S. Karger AG, Basel
2021
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
